The significant drop in Regeneron's stock price and the subsequent legal action are likely to negatively impact investor sentiment and the stock's short-term performance. The $9 billion loss in market value and the class action lawsuit suggest potential issues with the company's financial disclosures or performance, which could lead to further volatility.